More on KLRS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+24.6% Growth)
- Ratings (8.9 Score)

Upcoming Events

- Earnings (8/19/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kalaris Therapeutics (NQ:KLRS)
Delayed: 4.33 --0 (-0%)
Prev. Close $4.33  
Open$4.33 
52 Wk High$ 
52 Wk Low$ 
Day High$4.33 
Day Low$4.33 
P/E N/A  
EPS$ 
Volume1,006 


Jun 15, 2026 05:32 AM TD Cowen Starts Kalaris (KLRS) at Buy
Jun 12, 2026 08:00 AM Kalaris to Present at Clinical Trials at the Summit 2026
May 14, 2026 06:53 AM Wedbush Starts Kalaris (KLRS) at Outperform
May 13, 2026 05:08 AM Kalaris (KLRS) PT Lowered to $25 at Citizens Ahead of Phase 1b/2 MAD data in 2027
May 12, 2026 04:26 PM Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c
May 12, 2026 12:21 PM Raymond James on Kalaris (KLRS): 'We continue to expect Kalaris to resume dosing in 2Q26 '
May 12, 2026 08:00 AM Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Apr 16, 2026 04:06 AM Morgan Stanley Starts Kalaris (KLRS) at Overweight
Mar 31, 2026 05:31 PM Raymond James maintains Strong Buy on Kalaris (KLRS) following management meetings
Mar 18, 2026 05:05 AM Citizens Reiterates Market Outperform Rating on Kalaris (KLRS)
View All Articles

Entities mentioned with KLRS

View All Entities